Opdivo® (nivolumab) – New indication
September 22, 2017 – Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab) injection, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).
Download PDF
